| # | Title | Journal | Year | Citations |
|---|
| 1 | Escape from Flatland 2: complexity and promiscuity | MedChemComm | 2013 | 800 |
| 2 | Minisci reactions: Versatile CH-functionalizations for medicinal chemists | MedChemComm | 2011 | 489 |
| 3 | Recent applications of multicomponent reactions in medicinal chemistry | MedChemComm | 2012 | 403 |
| 4 | Quinolone antibiotics | MedChemComm | 2019 | 383 |
| 5 | Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives | MedChemComm | 2016 | 359 |
| 6 | Molecular obesity, potency and other addictions in drug discovery | MedChemComm | 2011 | 296 |
| 7 | ADMET-score – a comprehensive scoring function for evaluation of chemical drug-likeness | MedChemComm | 2019 | 295 |
| 8 | A systematic analysis of atomic protein–ligand interactions in the PDB | MedChemComm | 2017 | 289 |
| 9 | Heterocyclic Schiff base transition metal complexes in antimicrobial and anticancer chemotherapy | MedChemComm | 2018 | 279 |
| 10 | Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications | MedChemComm | 2010 | 266 |
| 11 | Silver nanoparticles—the real “silver bullet” in clinical medicine? | MedChemComm | 2010 | 264 |
| 12 | Imidazoles as potential anticancer agents | MedChemComm | 2017 | 262 |
| 13 | Chemical space as a source for new drugs | MedChemComm | 2010 | 257 |
| 14 | Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space | MedChemComm | 2011 | 256 |
| 15 | Ionic liquids as a potential tool for drug delivery systems | MedChemComm | 2016 | 216 |
| 16 | Chiral 1,1-diaryl compounds as important pharmacophores | MedChemComm | 2013 | 214 |
| 17 | Isatin and its derivatives: a survey of recent syntheses, reactions, and applications | MedChemComm | 2019 | 202 |
| 18 | Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype | MedChemComm | 2019 | 197 |
| 19 | Towards understanding cell penetration by stapled peptides | MedChemComm | 2015 | 183 |
| 20 | Towards biocompatible nanovalves based on mesoporous silica nanoparticles | MedChemComm | 2011 | 170 |
| 21 | 8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential | MedChemComm | 2015 | 169 |
| 22 | Antisense oligonucleotides: modifications and clinical trials | MedChemComm | 2014 | 165 |
| 23 | Nanoparticles vs. biofilms: a battle against another paradigm of antibiotic resistance | MedChemComm | 2016 | 158 |
| 24 | Are pyridazines privileged structures? | MedChemComm | 2011 | 156 |
| 25 | SLC transporters: structure, function, and drug discovery | MedChemComm | 2016 | 152 |
| 26 | 1,2,3-Triazole derivatives as antitubercular agents: synthesis, biological evaluation and molecular docking study | MedChemComm | 2015 | 148 |
| 27 | The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others? | MedChemComm | 2012 | 144 |
| 28 | The use of phosphate bioisosteres in medicinal chemistry and chemical biology | MedChemComm | 2012 | 140 |
| 29 | Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets | MedChemComm | 2011 | 138 |
| 30 | Narrow-spectrum antibacterial agents | MedChemComm | 2018 | 135 |
| 31 | Design, synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents | MedChemComm | 2010 | 132 |
| 32 | Strategies to prolong the plasma residence time of peptidedrugs | MedChemComm | 2010 | 130 |
| 33 | An insight into the therapeutic potential of quinazoline derivatives as anticancer agents | MedChemComm | 2017 | 128 |
| 34 | Antimycobacterial activity of spirooxindolo-pyrrolidine, pyrrolizine and pyrrolothiazole hybrids obtained by a three-component regio- and stereoselective 1,3-dipolar cycloaddition | MedChemComm | 2011 | 126 |
| 35 | Approaches to discover non-ATP site kinase inhibitors | MedChemComm | 2013 | 125 |
| 36 | On the origins of drug polypharmacology | MedChemComm | 2013 | 124 |
| 37 | Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance | MedChemComm | 2012 | 120 |
| 38 | A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics | MedChemComm | 2017 | 118 |
| 39 | Bacterial lipid membranes as promising targets to fight antimicrobial resistance, molecular foundations and illustration through the renewal of aminoglycoside antibiotics and emergence of amphiphilic aminoglycosides | MedChemComm | 2016 | 110 |
| 40 | Significantly improving the solubility of non-steroidal anti-inflammatory drugs in deep eutectic solvents for potential non-aqueous liquid administration | MedChemComm | 2016 | 110 |
| 41 | β-lactam/β-lactamase inhibitor combinations: an update | MedChemComm | 2018 | 110 |
| 42 | Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects | MedChemComm | 2015 | 109 |
| 43 | Targeting Brd4 for cancer therapy: inhibitors and degraders | MedChemComm | 2018 | 109 |
| 44 | Development of novel ionic liquids based on ampicillin | MedChemComm | 2012 | 105 |
| 45 | The synthesis and functional evaluation of a mitochondria-targeted hydrogen sulfide donor, (10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5-yl)phenoxy)decyl)triphenylphosphonium bromide (AP39) | MedChemComm | 2014 | 104 |
| 46 | Antimalarial peroxides: advances in drug discovery and design | MedChemComm | 2012 | 102 |
| 47 | Developing degraders: principles and perspectives on design and chemical space | MedChemComm | 2019 | 102 |
| 48 | Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics | MedChemComm | 2019 | 101 |
| 49 | TrxR inhibition and antiproliferative activities of structurally diverse gold N-heterocyclic carbene complexes | MedChemComm | 2013 | 99 |
| 50 | A fundamental view of enthalpy–entropy compensation | MedChemComm | 2014 | 98 |
